December 2004
Worldwide Biotech;Dec2004, Vol. 16 Issue 12, p1
Trade Publication
Reports on the acquisition of the patent license to the clinical-stage compound pumosetrag from Mitsubishi Pharma Corporation by Dynogen Pharmaceuticals Inc. Clinical information on pumosetrag; Coverage of the license acquired by Dynogen; Comments given by Lee R. Brettman, president and CEO of Dynogen, regarding the acquisition of pumosetrag.


Related Articles

  • Apex Bioventures Acquiring Dynogen in $135M Stock Deal. Hollingsworth, Catherine // BioWorld Today;2/7/2008, Vol. 19 Issue 26, p1 

    The article reports on a definitive merger agreement between Apex Bioventures Acquisition Corp. and privately held Dynogen Pharmaceuticals Inc., in a stock deal valued at more than $140 million. Under the deal, Waltham, Massachusetts-based Dynogen would receive an up-front payment of $98 million...

  • Restructuring Watch.  // BioWorld Today;2/26/2009, Vol. 20 Issue 37, p4 

    The article announces that Dynogen Pharmaceuticals Inc. has filed for bankruptcy, with an intention to liquidate under Chapter 7 of the U.S. bankruptcy code. The firm made two attempts in 2008 to increase its finances, first filing for an initial public offering (IPO), and then looking for a...

  • CLINIC ROUNDUP.  // BioWorld Today;11/9/2007, Vol. 18 Issue 219, p2 

    This section offers news briefs concerning clinical trials. CV Therapeutics Inc. reported that a preclinical study of tecadenoson, a selective adenosine A1 agonist, showed effective rate control in an animal model of atrial fibrillation when used with low dose metoprolol. The Phase IIb trial of...

  • Apex Bioventures to Acquire Dynogen: $135M.  // Bioworld Week;2/11/2008, Vol. 16 Issue 6, p4 

    The article reports on the plan to merge Apex Bioventures Acquisition Corp. of Hillsborough, California to Dynogen Pharmaceuticals Inc. in Waltham, Massachusetts in a stock deal valued at $135 million. Under the agreement, Dynogen receives an up-front payment and two milestone payments, while...

  • Apex Bioventures and Dynogen sign definitive merger agreement.  // PharmaWatch: Biotechnology;Mar2008, Vol. 7 Issue 3, p18 

    The article focuses on the definitive merger agreement between Apex Bioventures Acquisition Corp. and Dynogen Pharmaceuticals Inc. The agreement provides that Dynogen will become a public company and that its shareholders will receive about $98 million in Apex's stock. It is expected that the...

  • CLINIC ROUNDUP.  // BioWorld Today;5/21/2008, Vol. 19 Issue 99, p5 

    This section offers news briefs concerning clinical trials. Treatment for the first patient in the Phase I study of Pegylated recombinant phenylalanine ammonia lyase (PEG-PAL) in phenylketonuria conducted by BioMarin Pharmaceutical Inc. has been initiated. Results from a Phase IIa trial of...

  • Selecting Leaders. Fernandez, Jorge E. // Executive Excellence;Feb2003, Vol. 20 Issue 2, p14 

    Focuses on the recruitment, selection and development practices of chief executive officers (CEO) in the U.S. Assessment of the behavioral style of CEO; Factors considered in promotion of executive; Behavioral characteristics of CEO.

  • Correction.  // Employee Benefit News;Jun2007, Vol. 21 Issue 8, p7 

    A correction to the article about Fred Barstein, founder and chief executive officer of 401Exchange, published in the April 15, 2007 issue, is presented.

  • WHAT MAGAZINES CEOS ARE READING.  // SGB;Mar/Apr2010, Vol. 43 Issue 2, p44 

    The article focuses on the favorite magazines of some chief executive officers including A. Stone Douglass, CEO of Orange 21, Bob Puccini, President Mizuno USA and Matt Rubel, CEO Collective Brands.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics